查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971570

自動化血液處理設備市場：按產品類型、組件、操作模式、最終用戶和應用分類 - 全球預測（2026-2032 年）

Automated Blood Processing Equipment Market by Product Type, Component, Mode Of Operation, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，自動化血液處理設備市場價值將達到 545.5 億美元，到 2026 年將成長至 591 億美元，到 2032 年將達到 966.2 億美元，複合年成長率為 8.50%。

主要市場統計數據
基準年 2025 545.5億美元
預計年份：2026年 591億美元
預測年份 2032 966.2億美元
複合年成長率 (%) 8.50%

對自動化血液處理系統進行策略性概述，重點在於改變輸血工作流程的臨床因素、監管壓力、互通性要求和技術融合。

自動化血液處理系統正處於臨床需求、營運效率和設備創新三者交會的十字路口。醫院、血庫、診斷檢查室和研究機構面臨越來越大的壓力，需要提高處理能力、減少人為錯誤，並增強從血液採集到成分製備的整個工作流程的可追溯性。為此，供應商正在推動自動化技術的發展，以支援全血、血漿、血小板和細胞療法的穩定處理，同時滿足嚴格的安全標準和監管要求。

透過識別自動化、人工智慧驅動的分析、遠端監控、供應鏈彈性和臨床檢驗的變革性變化，這些要素正在共同重新定義全球血液處理操作。

自動化血液處理環境正因多種因素的共同作用而快速發展。首先，機器人、感測器和使用者介面技術的成熟使得設備能夠以可重複的品質執行複雜的血液分離任務，從而減少人為操作的差異並提高處理能力。同時，流程自動化、數據分析和數位化追溯的軟體創新正在改變價值提案，使其從獨立設備轉向支援端到端工作流程的整合解決方案。

評估 2025 年美國關稅對供應鏈、資本投資決策、跨境採購、零件採購以及整個價值鏈價格結構的累積影響。

美國將於2025年實施的關稅調整正在影響依賴進口零件和設備的企業的採購趨勢、供應商選擇和營運規劃。設備製造商和採購商必須考慮到岸成本的變化、供應商合約的重組以及零件交付可能出現的延誤，所有這些都會影響資本支出週期和備件供應。為此，各企業正在重新審視籌資策略，以平衡成本、品質和前置作業時間。

透過產品類型、組件類別、最終用戶概況、操作模式和臨床應用領域等關鍵細分洞察，可以影響購買行為、服務模式和投資回報率指標。

詳細的細分分析揭示了臨床優先事項和營運需求如何影響不同設備和服務類別的採購選擇。產品類型的差異，例如自動離心機、細胞分離系統、血漿分離系統和全血處理系統，決定了買家優先考慮的技術規格，包括處理能力、無菌控制和整合終點。同時，耗材、配件、設備和軟體/服務等組件的考量決定了持續的成本結構，並透過專有耗材生態系統影響供應商鎖定。

區域趨勢和實施模式（北美和南美、歐洲、中東和非洲以及亞太地區）正在塑造監管協調、償還途徑和在地化商業化策略。

區域趨勢反映了監管環境、報銷機制和普及速度的差異，決定了技術的傳播範圍和方式。在美洲，大規模綜合醫療保健系統和集中式血液服務往往主導採購決策，優先考慮規模、互通性和已證實的臨床療效。在歐洲、中東和非洲，法規結構和基礎設施成熟度各不相同，協調工作和區域報銷政策決定了打入市場策略和經銷夥伴。在亞太地區，主要大都市地區的快速普及正在推進，同時國內製造業和對區域卓越中心的投資也不斷成長。

競爭格局及主要企業洞察：涵蓋創新組合、策略聯盟、製造地、售後服務與市場進入差異化策略

競爭格局的核心在於設備設計、耗材生態系統、軟體驅動的工作流程、服務交付的創新。主要企業透過投資自動化可靠性、易用性和檢驗的臨床通訊協定來脫穎而出，從而降低醫院和血站採用這些技術的門檻。與臨床機構和研究中心建立策略合作夥伴關係，正在加速證據的產生並拓展應用場景，尤其是在細胞療法和富血小板血漿處理等新興應用領域。

對產業領導者的具體建議：策略採購、模組化產品設計、監管合作、臨床證據產生以及促進推廣和降低風險的商業模式。

產業領導者應採取一系列切實可行、基於實證的措施，在降低營運風險的同時加快部署速度。首先，應優先考慮互通性，採用開放的通訊標準，並設計和選擇已驗證可與實驗室資訊系統和電子健康記錄系統整合的設備。這將減少部署過程中的摩擦，並確保工作流程的連續性。其次，應投資於模組化產品架構和檢驗的用例庫，以實現分階段部署，並最大限度地減少臨床檢驗期間的中斷。

為了確保分析的嚴謹性和可重複性，我們系統性地結合了以下調查方法：與專家進行初步諮詢、有針對性的二次調查、三角測量通訊協定和品質保證程序。

研究途徑結合了結構化的專家參與和有針對性的二次檢驗，以確保研究結果的平衡性和可重複性。主要資訊來源包括與輸血醫學臨床負責人、採購經理、檢查室營運經理和設備工程師的諮詢，以深入了解工作流程需求、檢驗挑戰和服務期望等方面的細微觀點。基於這些訪談提出的假設，會根據已記錄的證據和技術規格進行檢驗。

全面整合，從臨床、製造和政策領域的相關人員中提取營運見解、策略重點、投資槓桿以及中短期行動計畫。

本分析整合了營運、監管和商業層面，為考慮實施自動化血液處理系統的相關人員提供統一的觀點。關鍵要點包括：在技術選擇過程中，必須平衡即時工作流程改善與長期互通性、可維護性和實證實踐。基於模組化檢驗和穩健的供應商夥伴關係制定實施計畫的機構，將最大限度地減少干擾，並確保在一致性和處理能力方面實現預期改進。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：自動化血液處理設備市場：依產品類型分類

  • 自動離心分離器
  • 細胞分離系統
  • 電漿分離系統
  • 全血處理系統

第9章 自動化血液處理設備市場：依組件分類

  • 耗材和配件
  • 裝置
  • 軟體和服務

第10章：自動化血液處理設備市場：依操作模式分類

  • 全自動
  • 半自動

第11章：自動化血液處理設備市場：以最終用戶分類

  • 血庫
  • 診斷檢查室
  • 醫院
  • 研究機構

第12章 自動化血液處理設備市場：依應用領域分類

  • 細胞療法
  • 透析
  • 血液療法
  • 富血小板血漿（PRP）製備

第13章：自動化血液處理設備市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：自動化血液處理設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 自動化血液處理設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國自動化血液處理設備市場

第17章：中國自動化血液處理設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Grifols SA
  • Haemonetics Corporation
  • Horiba Ltd.
  • Immucor, Inc.
  • Mindray Medical International Limited
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Terumo Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-535C62918B29

The Automated Blood Processing Equipment Market was valued at USD 54.55 billion in 2025 and is projected to grow to USD 59.10 billion in 2026, with a CAGR of 8.50%, reaching USD 96.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 54.55 billion
Estimated Year [2026] USD 59.10 billion
Forecast Year [2032] USD 96.62 billion
CAGR (%) 8.50%

Strategic overview of automated blood processing equipment highlighting clinical drivers, regulatory pressures, interoperability demands, and technological convergence transforming transfusion workflows

Automated blood processing equipment stands at the intersection of clinical need, operational efficiency, and device innovation. Hospitals, blood banks, diagnostic laboratories, and research institutes face increasing pressure to improve throughput, reduce manual handling errors, and strengthen traceability across blood collection and component preparation workflows. In response, vendors are advancing automation to support consistent processing of whole blood, plasma, platelets, and cellular therapies while addressing stringent safety and regulatory expectations.

Stakeholders now evaluate technology not only for its hardware capabilities but for its ability to integrate with laboratory information systems, electronic health records, and cloud analytics platforms. This emphasis on interoperability elevates software and services as critical components of value propositions. At the same time, consumables and accessories remain central to operational continuity and recurring revenue models. As a result, procurement decisions increasingly hinge on lifecycle costs, service agreements, and the depth of evidence supporting clinical outcomes.

Transitioning from manual to automated workflows requires coordinated clinical validation, staff training, and change management. Institutions that plan for phased deployment, proactive quality management, and stakeholder alignment can accelerate adoption while safeguarding patient safety. Consequently, strategic clarity around technology roadmaps and vendor commitments is now a prerequisite for successful implementation and long-term operational resilience.

Identifying transformative shifts in automation, AI-enabled analytics, remote monitoring, supply chain resilience, and clinical validation that are collectively redefining blood processing operations worldwide

The landscape for automated blood processing is evolving rapidly under several converging forces. First, technological maturation in robotics, sensors, and user interfaces has enabled devices to perform complex fractionation tasks with reproducible quality, reducing manual variability and improving throughput. Concurrently, software innovations-particularly in process automation, data analytics, and digital traceability-are shifting the value proposition from standalone instruments to integrated solutions that support end-to-end workflows.

Regulatory expectations and clinical evidence demands have intensified, prompting manufacturers to design devices that facilitate validation, auditability, and compliance. In parallel, clinical programs such as cell therapy and expanded platelet-rich plasma applications are driving demand for equipment capable of precise, sterile processing with minimal human intervention. Supply chain resilience has also risen in priority; institutions now evaluate manufacturers on the stability of their consumable supply, geographic manufacturing footprint, and contingency planning.

Finally, consolidation and partnership models between device producers, diagnostic laboratories, and healthcare providers are accelerating. These collaborations aim to combine clinical expertise, distribution reach, and service capabilities to reduce time-to-market and improve post-sale support. Taken together, these shifts are not incremental; they are reframing vendor selection, procurement timing, and long-term service relationships across healthcare organizations.

Assessing the cumulative impact of United States tariffs 2025 on supply chains, capital investment decisions, cross-border procurement, component sourcing, and pricing structures across the value chain

The United States tariff adjustments introduced in 2025 are affecting procurement dynamics, supplier selection, and operational planning for institutions that depend on imported components and instruments. Equipment manufacturers and buyers must now account for altered landed costs, reconfigured supplier contracts, and potential delays in component delivery, all of which influence capital expenditure cycles and spare-parts availability. In response, organizations are reassessing sourcing strategies to balance cost, quality, and lead time.

Manufacturers with diversified production footprints and regional assembly capabilities can mitigate tariff exposure and maintain service levels. At the same time, buyers are placing greater emphasis on total cost of ownership evaluations that incorporate duties, logistics risk, and aftermarket service resilience. Transitional strategies include renegotiating long-term supply agreements, increasing local inventory buffers for critical consumables, and qualifying alternative component suppliers to reduce single-source vulnerabilities.

Regulatory and procurement teams should also anticipate that tariff-driven pricing shifts could accelerate interest in domestically produced solutions or in products assembled closer to end markets. As a result, capital planning and vendor engagement must become more agile, with provisions for scenario modeling and contingency financing. Ultimately, the tariff environment is prompting a strategic recalibration of supply chain architecture and procurement policies in the short and medium term.

Key segmentation insights across product types, component categories, end-user profiles, modes of operation, and clinical applications that influence purchasing behavior, service models, and ROI metrics

A granular understanding of segmentation reveals how clinical priorities and operational requirements drive procurement choices across distinct device and service categories. Product type differentiation between Automated Centrifuges, Cell Separation Systems, Plasma Separation Systems, and Whole Blood Processing Systems shapes the technical specifications buyers prioritize, such as throughput, sterility controls, and integration endpoints. Meanwhile, component considerations across Consumables & Accessories, Instruments, and Software & Services determine recurring cost profiles and influence vendor lock-in due to proprietary consumable ecosystems.

End-user characteristics vary substantially between Blood Banks, Diagnostic Laboratories, Hospitals, and Research Institutes, with each cohort valuing different performance attributes; for example, blood banks emphasize donor throughput and component yield stability, diagnostic laboratories prioritize traceability and integration with LIS, hospitals demand compact footprint and service responsiveness, and research institutes prioritize flexibility for experimental protocols. Mode of operation distinctions-Fully Automated versus Semi Automated-further inform workflow redesign, staffing implications, and training needs, with fully automated systems reducing hands-on time but requiring higher upfront validation.

Application-specific demands across Cell Therapy, Dialysis, Hemotherapy, and Platelet Rich Plasma Preparation introduce specialized validation, sterility, and regulatory requirements that influence design choices and commercial positioning. Manufacturers that align product roadmaps with these layered segmentation insights can craft clearer value propositions, optimize aftermarket packages, and design commercial models aligned with each buyer persona.

Regional dynamics and adoption patterns across Americas, Europe Middle East & Africa, and Asia-Pacific shaping regulatory harmonization, reimbursement pathways, and localized commercialization strategies

Regional dynamics reflect differing regulatory regimes, reimbursement landscapes, and adoption curves that shape where and how technologies gain traction. In the Americas, procurement decisions are often driven by large integrated health systems and centralized blood services that prioritize scale, interoperability, and proven clinical outcomes. Europe, Middle East & Africa present a mosaic of regulatory frameworks and infrastructure maturity levels, where harmonization efforts and localized reimbursement policies dictate market entry strategies and distribution partnerships. Asia-Pacific exhibits rapid adoption in major metropolitan centers alongside growing investment in domestic manufacturing and regional centers of excellence.

These geographic nuances affect logistical planning, training models, and service networks. For example, regions with centralized blood services can adopt standardized protocols more rapidly, enabling faster roll-out of automated solutions, whereas diverse regulatory contexts require tailored evidence packages and iterative local validation. Manufacturers that invest in regional training hubs, multilingual clinical support, and localized spare-parts stocking can reduce implementation friction and improve customer satisfaction.

Moreover, regional procurement practices influence commercial structures; some markets favor capital purchase models while others increasingly evaluate managed-service or reagent-as-a-service arrangements. Understanding these distinctions is essential to designing scalable market entry strategies and sustainable after-sales programs across the Americas, Europe Middle East & Africa, and Asia-Pacific.

Competitive landscape and key company insights covering innovation portfolios, strategic partnerships, manufacturing footprints, aftermarket services, and go-to-market differentiation strategies

The competitive environment centers on innovation in instrument design, consumable ecosystems, software-enabled workflows, and service delivery. Leading companies differentiate through investments in automation reliability, ease of use, and validated clinical protocols that lower the barrier to adoption for hospitals and blood centers. Strategic partnerships with clinical institutions and research centers accelerate evidence generation and expand use cases, particularly in emerging applications like cell therapy and platelet-rich plasma processing.

Manufacturers that prioritize modular architectures and open interfaces position themselves favorably for integration into hospital and laboratory IT ecosystems. Aftermarket services, including rapid spare-part fulfillment, remote diagnostics, and subscription-based consumable programs, are increasingly critical levers for customer retention and recurring revenue. Additionally, localized manufacturing and regional distribution partnerships offer a competitive edge in markets sensitive to tariff fluctuations and logistics disruption.

New entrants face a high bar for clinical validation and scale, but they can compete by focusing on niche applications or novel process efficiencies. Established players, in contrast, can invest in incremental innovations and global service networks to defend market positions. Ultimately, successful companies combine product excellence with robust clinical evidence, predictable service models, and clear total-cost-of-ownership narratives.

Actionable recommendations for industry leaders on strategic sourcing, modular product design, regulatory engagement, clinical evidence generation, and commercial models to accelerate adoption and mitigate risk

Industry leaders should adopt a set of pragmatic, evidence-driven actions to accelerate adoption while mitigating operational risk. First, prioritize interoperability by designing or selecting devices with open communication standards and proven integration with laboratory information systems and electronic health records; doing so reduces implementation friction and preserves workflow continuity. Second, invest in modular product architectures and validated use-case libraries that allow phased deployment, minimizing disruption during clinical validation.

Third, strengthen supply chain resilience by diversifying component sources, maintaining regional inventory buffers for critical consumables, and establishing contingency plans for cross-border disruptions. Fourth, align commercial models to customer needs by offering flexible procurement options, including managed-service contracts, reagent-subscription programs, and bundled validation support that lower upfront barriers for buyers. Fifth, accelerate clinical acceptance through targeted evidence generation programs, peer-led training, and published real-world use cases that demonstrate clinical and operational advantages.

Finally, embed continuous service improvement via remote monitoring, predictive maintenance, and outcome-linked service metrics to enhance customer satisfaction and reduce downtime. Executed in concert, these measures create a compelling value proposition for buyers while reducing the risk and friction associated with technology transitions in critical blood processing workflows.

Research methodology detailing a systematic blend of primary expert consultations, targeted secondary research, triangulation protocols, and quality assurance procedures to ensure analytical rigor and reproducibility

The research approach combined structured primary engagement with subject-matter experts and targeted secondary validation to ensure balanced, reproducible findings. Primary input included consultations with clinical leaders in transfusion medicine, procurement executives, laboratory operations managers, and device engineers to capture nuanced perspectives on workflow requirements, validation pain points, and service expectations. These interviews informed hypotheses that were subsequently tested against documentary evidence and technical specifications.

Secondary research encompassed regulatory submissions, peer-reviewed clinical literature, product manuals, and publicly available company disclosures to verify claims and identify technology trends. Data synthesis relied on triangulation protocols to reconcile differing perspectives and to surface consistent themes across stakeholders. Quality assurance procedures included cross-review by independent analysts and iterative validation with domain experts to ensure methodological transparency.

Where possible, findings emphasized observable developments-such as adoption patterns, integration demands, and procurement behaviors-while avoiding speculative projections. The methodology prioritized traceable sources and repeatable techniques so that institutions can replicate the analytic steps for their specific contexts, ensuring that strategic decisions rest on a defensible evidence base.

Concluding synthesis that distills operational implications, strategic priorities, investment levers, and short-to-medium term action plans for stakeholders across clinical, manufacturing, and policy domains

The analysis synthesizes operational, regulatory, and commercial dimensions to create a unified perspective for stakeholders navigating automated blood processing adoption. The primary implication is that technology selection must balance immediate workflow gains with longer-term interoperability, serviceability, and evidence generation commitments. Institutions that plan deployments around modular validation and robust supplier partnerships will minimize disruption and capture the expected improvements in consistency and throughput.

Strategic priorities should include investing in staff training, aligning procurement practices with lifecycle cost assessments, and developing clinical validation plans that produce publishable outcomes. For manufacturers, the path forward involves deepening integration capabilities, expanding service offerings, and supporting regional manufacturing or distribution to minimize tariff and logistics exposure. Collaboration between providers and device makers-centered on shared protocols and outcome measurement-will accelerate real-world adoption and build trust among clinical users.

In closing, stakeholders that act deliberately-anchoring decisions to operational readiness, evidence requirements, and resilient supply strategies-will be best positioned to realize the clinical and economic benefits of automation in blood processing while minimizing implementation risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automated Blood Processing Equipment Market, by Product Type

  • 8.1. Automated Centrifuges
  • 8.2. Cell Separation Systems
  • 8.3. Plasma Separation Systems
  • 8.4. Whole Blood Processing Systems

9. Automated Blood Processing Equipment Market, by Component

  • 9.1. Consumables & Accessories
  • 9.2. Instruments
  • 9.3. Software & Services

10. Automated Blood Processing Equipment Market, by Mode Of Operation

  • 10.1. Fully Automated
  • 10.2. Semi Automated

11. Automated Blood Processing Equipment Market, by End User

  • 11.1. Blood Banks
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Automated Blood Processing Equipment Market, by Application

  • 12.1. Cell Therapy
  • 12.2. Dialysis
  • 12.3. Hemotherapy
  • 12.4. Platelet Rich Plasma Preparation

13. Automated Blood Processing Equipment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Automated Blood Processing Equipment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Automated Blood Processing Equipment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Automated Blood Processing Equipment Market

17. China Automated Blood Processing Equipment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Becton, Dickinson and Company
  • 18.7. bioMerieux SA
  • 18.8. Danaher Corporation
  • 18.9. F. Hoffmann-La Roche Ltd
  • 18.10. Grifols S.A.
  • 18.11. Haemonetics Corporation
  • 18.12. Horiba Ltd.
  • 18.13. Immucor, Inc.
  • 18.14. Mindray Medical International Limited
  • 18.15. Siemens Healthineers AG
  • 18.16. Sysmex Corporation
  • 18.17. Terumo Corporation
  • 18.18. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY AUTOMATED CENTRIFUGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY AUTOMATED CENTRIFUGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY AUTOMATED CENTRIFUGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL SEPARATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL SEPARATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL SEPARATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLASMA SEPARATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLASMA SEPARATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLASMA SEPARATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY WHOLE BLOOD PROCESSING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY WHOLE BLOOD PROCESSING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY WHOLE BLOOD PROCESSING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY FULLY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY FULLY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY FULLY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SEMI AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SEMI AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SEMI AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLATELET RICH PLASMA PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLATELET RICH PLASMA PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLATELET RICH PLASMA PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 117. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 135. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 141. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)